Variant Bio, a small biotech company based in Seattle, is using genetic information from Indigenous people to develop drugs for obesity and diabetes.
In 2019, Stephane Castel, the CEO struck an unusual bargain with the locals to receive a share of the company’s revenues in exchange for entrusti
```
Members Only
Login or create an account to continue
This article is available to registered BusinessDay readers. Please login if you already have an account, or create a new account to continue reading.
New to BusinessDay? Register now and start reading.
```
